Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon

Journal of Medical Virology

Volumn 78, Issue 3, 2006, Pages 365-371

  Boulestin, Anne ^a   Kamar, Nassim ^b   Sandres Sauné, Karine ^a   Legrand Abravanel, Florence ^a   Alric, Laurent ^a   Vinel, Jean Pierre ^a   Rostaing, Lionel ^b   Izopet, Jacques ^a  

^a CHU PURPAN   (France)

^b Unité de Transplantation d'Organes   (France)

Author keywords

Alpha interferon; Baseline viral load; Genotype; Hepatitis C; Viral dynamics

Indexed keywords

ALPHA INTERFERON; VIRUS RNA;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CELL KINETICS; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; STRAIN IDENTIFICATION; VIREMIA; VIRUS LOAD; VIRUS RESISTANCE;

ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD; VIREMIA;

HEPATITIS C VIRUS;

EID: 33644662994     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20548     Document Type: Article

References (41)

1. Al-Faleh FZ, Aljumah A, Rezeig M, Al K, Al-Otaibi M, Alahdal M, Al-Humayed S, Mayet I, Al-Juhani M, Al-Karawi M, George K, Sbeih F. 2000. Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study. J Viral Hepat 7:287-291.
2. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. 1997. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology 26:1378-1428.
3. Bressler BL, Guindi M, Tomlinson G, Heathcote J. 2003. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38:639-644.
4. Chatelut E, Rostaing L, Gregoire N, Payen JL, Pujol A, Izopet J, Houin G, Canal P. 1999. A pharmacokinetic model for alpha interferon administered subcutaneously. Br J Clin Pharmacol 47:365-371.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975-982.
6. Goodbourn S, Didcock L, Randall RE. 2000. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 81:2341-2364.
7. Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. 2000. Hepatitis C virus kinetics. Antivir Ther 5:85-90.
8. Hoofnagle JH, Di Bisceglie AM. 1997. The treatment of chronic viral hepatitis. N Engl J Med 336:347-356.
9. Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. 2003. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 187:1071-1074. Epub 2003 Mar 1077.
10. Izopet J, Payen JL, Alric L, Sandres K, Charlet JP, Vinel JP, Duffaut M, Pascal JP, Puel J. 1998. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J Med Virol 54:86-91.
11. Jessner W, Gschwantler M, Steindl-Munda P, Hofer H, Watkins-Riedel T, Wrba F, Mueller C, Gangl A, Ferenci P. 2001. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet 358:1241-1242.
12. Jessner W, Watkins-Riedel T, Formann E, Steindl-Munda P, Ferenci P. 2002. Hepatitis C viral dynamics: basic concept and clinical significance. J Clin Virol 25:831-39.
13. Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P. 2003. Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection. J Viral Hepat 10:37-42.
14. Karino Y, Toyota J, Sugawara M, Miyazaki K, Kuwata Y, Yamazaki K, Sato T, Ohmura T, Matsushima T. 2003. Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 18:404-410.
15. Kozlowski A, Harris JM. 2001. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release 72:217-224.
16. Lau JY, Davis GL, Prescott LE, Maertens G, Lindsay KL, Qian K, Mizokami M, Simmonds P. 1996. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Ann Intern Med 124:868-876.
17. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. 2003. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37:1343-1350.
18. Lee SS, Abdo AA. 2003. Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon? J Antimicrob Chemother 51:487-491.
19. Lee SS, Heathcote EJ, Reddy KR, Zeuzem S, Fried MW, Wright TL, Pockros PJ, Haussinger D, Smith CI, Lin A, Pappas SC. 2002. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). Journal of Hepatology 37:500-506.
20. Legrand-Abravanel F, Sandres-Saune K, Barange K, Alric L, Moreau J, Desmorat P, Vinel JP, Izopet J. 2004. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis 189:1397-1400. Epub 2004 Apr 1391.
21. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958-965.
22. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, Benhamou J, Erlinger S. 1995. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 22:1050-1056.
23. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339:1485-1492.
24. Missale G, Cariani E, Lamonaca V, Ravaggi A, Rossini A, Bertoni R, Houghton M, Matsuura Y, Miyamura T, Fiaccadori F, Ferrari C. 1997. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients. Hepatology 26:792-797.
25. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107.
26. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ. 2000. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 182:28-35.
27. NIH. 2002. Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 19:1-46.
28. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. 2000. Standardization of hepatitis C virus RNA quantification. Hepatology 32:654-659.
29. Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, Dussaix E, Voigt JJ, Selves J, Barange K, Puel J, Pascal JP. 1998. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'etude et De Traitement du Virus De L'hepatite C (Get.Vhc). Hepatology 28:1680-1686.
30. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432.
31. Sandres-Saune K, Deny P, Pasquier C, Thibaut V, Duverlie G, Izopet J. 2003. Determining hepatitis C genotype by analyzing the sequence of the NS5b region. J Virol Methods 109:187-193.
32. Shobokshi OA, Serebour FE, Skakni L, Al-Jaser N, Tantawe AO, Sabah A, Dinish T, Al-Quaiz M, Qatani K, Sandokji A, Al-Blowi A, Karawi M, Al Kayyal B, Al-Momen S, Akbar H, Ayoola A, El-Hazmi M, El-Hazmi I, Humaida A, Eissa H, Khawajah F, Al-Khalifa M. 2003a. Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of pegylated interferon plus ribavirin. Saudi Med J 24:S92-S93.
33. Shobokshi OA, Serebour FE, Skakni L, Al-Jaser N, Tantawe AO, Sabah A, Dinish T, Al-Quaiz M, Qatani K, Sandokji A, Al-Blowi A, Karawi M, Al-Kayyal B, Al-Momen S, Akbar H, Ayoola A, El-Hazmi M, El-Hazmi I, Humaida A, Eissa H, Khawajah F, Al-Khalifa M. 2003b. Pegylated interferon alfa-2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Med J 24:892.
34. Smith DB, Davidson F, Yap P, Brown H, Kolberg J, Detmer J, Urdea M, Simmonds P, International HCVC. 1996. Levels of hepatitis C virus in blood donors infected with different viral genotypes. International HCV Collaborative Study Group. J Infect Dis 173:727-730.
35. Torre F, Giusto R, Grasso A, Brizzolara R, Campo N, Sinelli N, Balestra V, Picciotto A. 2001. Clearance kinetics of hepatitis C virus under different antiviral therapies. J Med Virol 64:455-459.
36. Wright TL. 2002. Treatment of patients with hepatitis C and cirrhosis. Hepatology 36:8185-194.
37. Yoshioka K, Aiyama T, Okumura A, Takayanagi M, Iwata K, Ishikawa T, Nagai Y, Kakumu S. 1997. Humoral immune response to the hypervariable region of hepatitis C virus differs between genotypes 1b and 2a. J Infect Dis 175:505-510.
38. Zein NN. 2000. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 13:223-235.
39. Zeuzem S. 2004. Heterogenous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who respond less well ? Ann Intern Med 140:370-381.
40. Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK. 1998. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 28:245-252.
41. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK. 2001. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 120:1438-1447.